Home-based intervention to test and start (HITS) protocol: a cluster-randomized controlled trial to reduce HIV-related mortality in men and HIV incidence in women through increased coverage of HIV treatment. by Mathenjwa, T et al.
LSHTM Research Online
Mathenjwa, T; Kim, H-Y; Zuma, T; Shahmanesh, M; Seeley, J; Matthews, P; Wyke, S; McGrath, N;
Sartorius, B; Yapa, HM; +5 more... Adeagbo, O; Blandford, A; Dobra, A; Bäernighausen, T; Tanser,
F; (2019) Home-based intervention to test and start (HITS) protocol: a cluster-randomized controlled
trial to reduce HIV-related mortality in men and HIV incidence in women through increased coverage
of HIV treatment. BMC Public Health, 19 (1). DOI: https://doi.org/10.1186/s12889-019-7277-0
Downloaded from: http://researchonline.lshtm.ac.uk/4653712/
DOI: https://doi.org/10.1186/s12889-019-7277-0
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
STUDY PROTOCOL Open Access
Home-based intervention to test and start
(HITS) protocol: a cluster-randomized
controlled trial to reduce HIV-related
mortality in men and HIV incidence in
women through increased coverage of HIV
treatment
T. Mathenjwa1* , H.-Y. Kim1, T. Zuma1, M. Shahmanesh1,2, J. Seeley1,3, P. Matthews1, S. Wyke4, N. McGrath1,5,
B. Sartorius6, H. M. Yapa1,7, O. Adeagbo1,11, A. Blandford8, A. Dobra9, T. Bäernighausen10 and F. Tanser1,12,13,14
Abstract
Background: To realize the full benefits of treatment as prevention in many hyperendemic African contexts, there
is an urgent need to increase uptake of HIV testing and HIV treatment among men to reduce the rate of HIV
transmission to (particularly young) women. This trial aims to evaluate the effect of two interventions - micro-
incentives and a tablet-based male-targeted HIV decision support application - on increasing home-based HIV
testing and linkage to HIV care among men with the ultimate aim of reducing HIV-related mortality in men and HIV
incidence in young women.
Methods/design: This is a cluster randomized trial of 45 communities (clusters) in a rural area in the uMkhanyakude
district of KwaZulu Natal, South Africa (2018–2021). The study is built upon the Africa Health Research Institute (AHRI)‘s
HIV testing platform, which offers annual home-based rapid HIV testing to individuals aged 15 years and above. In a
2 × 2 factorial design, individuals aged ≥15 years living in the 45 clusters are randomly assigned to one of four arms: i)
a financial micro-incentive (food voucher) (n = 8); ii) male-targeted HIV specific decision support (EPIC-HIV) (n = 8); iii)
both the micro incentives and male-targeted decision support (n = 8); and iv) standard of care (n = 21). The EPIC-HIV
application is developed and delivered via a tablet to encourage HIV testing and linkage to care among men. A mixed
method approach is adopted to supplement the randomized control trial and meet the study aims.
Discussion: The findings of this trial will provide evidence on the feasibility and causal impact of two interventions -
micro-incentives and a male-targeted HIV specific decision support - on uptake of home-based HIV testing, linkage to
care, as well as population health outcomes including population viral load, HIV related mortality in men, and HIV
incidence in young women (15-30 years of age).
Trial registration: This trial was registered on 28 November 2018 on, identifier https://clinicaltrials.gov/.
Keywords: HIV, Home-based HIV testing, Financial incentives, Counselling, Linkage to care
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Background
Early initiation of antiretroviral therapy (ART) has the dual
benefit of increasing life expectancy for people living with
HIV and preventing onward HIV transmission to unin-
fected individuals [1, 2]. In sub-Saharan Africa, the wide-
spread scale-up of ART has reduced HIV-related deaths by
almost half and led to substantial declines in new HIV in-
fections [1]. For example, in a rural area in Northern Kwa-
Zulu-Natal, South Africa, a 1% increase in community-
level ART coverage was associated with a 1% reduction in
the individual risk of HIV acquisition [2]. However, the
overall HIV incidence rates remain high in this setting, and
young women are disproportionately at a risk of HIV infec-
tion [3]. HIV-related mortality among men also remains
comparatively high despite the mass provision of free ART
in public health care facilities [4, 5]. These two challenges
to current HIV programs – continued high HIV incidence
in women and comparatively high HIV-related mortality in
men – are inextricably linked. The key contributing factors
are that men are less likely to test for HIV and far less likely
to link to care if tested HIV positive [6], putting them at a
greater risk of HIV-related death, as well as HIV transmis-
sion to their sexual partners.
To realize the full benefits of treatment as prevention, it
is urgent to increase uptake of HIV testing and HIV treat-
ment among men who are living with HIV and at high risk
of transmitting HIV to their sexual partners. Behavioural
economics suggests that relatively small financial incentives
can be used to “nudge” individuals towards healthy behav-
iours [7], particularly simple behavioural changes, such as
agreeing to a rapid HIV test or making clinic appoint-
ments. Incentives have been shown as effective in increas-
ing one-off behaviours, such as vaccinations [8], tuberculin
screening testing [9], circumcision [10], or uptake of pre-
ventative health counselling in low- and middle-income
countries [11]. However, the causal impact of one-off finan-
cial incentives for HIV testing and linkage to care on long-
term population-level benefits such as reducing HIV inci-
dence has not been established.
On the other hand, long-term linkage to care involves
repeated trips to the clinic which require ongoing intrin-
sic motivation. Yet, financial incentives tend to focus on
short-term behavioural changes and operate via extrinsic
motivation, which could potentially crowd out intrinsic
motivation [12, 13]. The benefits of testing and early ini-
tiation of ART are also not widely understood or ac-
cepted by many men, often delaying HIV testing and
linkage to care after diagnosis [14]. In the treatment as
prevention (TasP) trial (ANRS 12249) conducted in
KwaZulu-Natal, South Africa, the majority of men who
did not consent for HIV testing reported feeling healthy
as a reason for being reluctant to test [15]. These bar-
riers to test and link to care are usually based on lack of
information, misinformation or lack of salience of the
information. Providing decision support in the form of
experiential information that describes the options avail-
able, allows clarification of personal values, and the need
to make specific decisions (to test or link) explicit [16]
could increase intrinsic motivation. Also, given the lower
level of testing and linkage to care among men com-
pared to women, decision support for HIV testing and
linkage to care needs to be tailored, flexible and gender
sensitive to reflect existing values and norms of men and
women, separately. Complementing financial incentives
with gender specific HIV counselling could be an effect-
ive strategy to increase both intrinsic and extrinsic mo-
tivation to test and link to HIV care.
We hypothesize that provision of micro-incentives and
male-targeted HIV-specific decision-support (imple-
mented via an android tablet-based application) would
enable people to make more informed choices and thus
increase uptake of home-based HIV testing and linkage
to care, leading to reduction in population viral load and
HIV-related mortality among men and ultimately lower
HIV incidence in young women. To test this hypothesis,
we designed a factorial cluster randomised controlled
trial for implementation in the uMkhanyakude district of
KwaZulu-Natal, South Africa.
Methods/design
Study design
The trial is delivered in a four strata using a 2 × 2 factorial
design to compare the effectiveness of two interventions,
micro-incentives and male-targeted HIV-specific decision-
support, called EPIC-HIV (Empowering People through In-
formed Choices for HIV), in 45 clusters (week blocks)
using the Africa Health Research Institute (AHRI)‘s HIV
surveillance platform (Fig. 1). The four strata are Arm 1
micro-incentives; Arm 2 both micro-incentives and EPIC-
HIV (male-targeted HIV decision-support); Arm 3 EPIC-
HIV (male-targeted HIV decision-support); and Arm 4
standard of care (SoC).The study protocol follows the
Standard Protocol Items: Recommendations for Interven-
tion Trials (SPIRIT) [17] and the Consolidated Standards
of Reporting Trials (CONSORT) statement for reporting
RCTs [18].
The study is registered at the National Institute for
Health’s ClinicalTrials.gov. Enrolment started in February
2018 and follow up will be completed in December 2021.
Participants
Inclusion criteria
Individuals are eligible if they are aged 15 years or older
and a resident member of the of households within the
AHRI HIV Surveillance southern area, agree to participate
in the annual HIV surveillance and willing to give written
informed consent for trial participation. Both males and
females are eligible to receive the micro-incentive
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component of the intervention but only males are eligible
to receive EPIC-HIV (male-targeted HIV decision-
support).
Exclusion criteria
Individuals are not eligible to receive any of the HITS
interventions if they have refused to participate in the
AHRI HIV surveillance or report to be already on ART.
Individuals mentally or physically challenged to provide
consent are also excluded.
Study setting
The trial is conducted in the Hlabisa sub-district of the
uMkhanyakude district located in northern KwaZulu-
Natal South Africa between 2018 and 2021 (Fig. 2). The
area is predominantly rural and has recorded one of the
highest population HIV prevalence estimates globally
[20]. In this sub-district, AHRI has one of the largest
population-based Demographic and HIV surveillance
since 2000. The surveillance covers 432 km2 geographic
area over approximately 100 000 individuals and 60 000
residents at any given time. Trained field-workers visit
Fig. 1 Allocation of the two interventions in four strata across 45 communities
Fig. 2 Location of the study area in South Africa: Taken from another source - Tanser et al. 2008 [19]. Not under copyright
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all households in the surveillance area and interview a
key resident informant annually. The household survey
records demographic components of households includ-
ing size, composition, fertility, migration, mortality, and
nuptiality. The HIV surveillance is annually conducted on
all resident individuals aged 15 years or older to collect sex-
ual behaviour and general health data and dried blood spots
(DBS) samples for anonymized HIV testing [21]. The field-
work visits are carried out in systematic cycles of 45 "week
blocks". A week block is a workload-equivalent area devel-
oped using a GPS based methodology [22]. AHRI works
closely with the local Department of Health in a compre-
hensive HIV Treatment and Care Programme, decentra-
lized to the 17 primary health care clinics in the sub-district.
HIV testing and treatment are available at all 17 primary
health care clinics and the district hospital. Since 2017,
AHRI has introduced home-based rapid HIV testing as part
of the annual HIV surveillance.
Interventions
The two interventions, micro-incentives and the male-
targeted HIV-specific decision support, are offered in a
two-stage scheme. The first stage is aimed at encour-
aging HIV testing (Fig. 3), while the second stage is
aimed at encouraging linkage to care if tested HIV posi-
tive (Fig. 4). Micro-incentives are in the form of a R50
food voucher (redeemable in a local supermarket) condi-
tional on undergoing a home-based rapid HIV test. If
diagnosed with HIV and present for HIV care in one of
the local Department of Health clinics servicing the pro-
gram area within 6 weeks of the HIV test, participants
receive a second R50 food voucher.
The male-targeted HIV-specific decision-support is
implemented via a tablet-based application called EPIC-
HIV. EPIC-HIV development was guided by a combin-
ation of human behaviour change theory and person-
based intervention design [23] and human computer
interaction techniques. The development process (de-
scribed elsewhere in more detail) included three phases:
1) a thorough review of literature was conducted to
synthesize key facilitators and barriers of HIV care and
management among men in South Africa; 2) the review
informed content, design features and format of the ap-
plication, and the app was iteratively prototyped; 3) the
Fig. 3 Study flow - 1st stage: interventions at the time of home-based HIV testing offer
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content was evaluated with the community advisory
board, and usability testing and in-depth interviews were
conducted with representative users at every iteration to
establish understanding of content and usability issues.
The content is rooted in local narratives and provided in
a form of experiential information to increase risk per-
ception, salience and likelihood of response [24, 25].
EPIC-HIV makes the decision to test or link to care ex-
plicit by providing experiential information about what
various outcomes might be like (imagined future). It fur-
ther supports three basic human ‘needs’ as defined by
the self-determination theory - the need for autonomy,
competence, and relatedness [26]. The app is available in
two versions (EPIC HIV-1 and EPIC HIV-2). EPIC-HIV
1 is offered to men at the point of HIV test offer prior to
HIV counselling and testing to support them when
choosing whether or not to test for HIV. If participants
are diagnosed with HIV but do not present in the local
Department of Health clinic within a month of the posi-
tive HIV test, a study tracker team re-visit participants
at home and offer EPIC-HIV 2, which is designed to ad-
dress barriers to seek HIV treatment and encourage
them to link to HIV care.
Male residents in the clusters that receive both interven-
tions are offered EPIC-HIV 1 prior to HIV testing, a food
voucher conditional on undergoing a rapid HIV test, and
a second food voucher when they link to care within 6
weeks of receiving an HIV positive test. If they do not link
to care within a month of the positive HIV test they be-
come eligible for EPIC-HIV 2. Female residents in these
clusters are eligible to receive the food voucher only. Resi-
dents in the control clusters receive standard of care
where they are offered the home-based HIV rapid test,
and if diagnosed with HIV, referred to the clinic for link-
age to HIV care.
Outcomes
The goal of the trial is to establish whether the provision
of micro-incentives and a male-targeted HIV-specific de-
cision-support app will increase uptake of HIV testing
and linkage to HIV care thus, ultimately reducing HIV-
related mortality in men and population-level HIV inci-
dence in young women. The trial’s primary endpoints
are to measure the impact of the interventions at both
individual and population-levels as follows:
1. HIV testing uptake at point of test offer in men
2. HIV treatment linkage in men at 1-year
3. Population-level HIV viral suppression in men after
1-year
Fig. 4 Study flow – 2nd stage: interventions at the time of linkage to care (Arm 1 and 2 for micro-incentives) or 1 month after HIV-positive test if
not linked to care (Arm 2 and 3 for EPIC-HIV 2)
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4. Population-level HIV-related mortality in men after
3-years
5. Population-level HIV incidence in young women
(15–30 years of age) after 3-years
Specifically, the study compares differences in the per-
centage that received the rapid HIV test at home among
those offered the test in men among the intervention arms
compared to the SoC arm. The study will also compare
the percentage who visited study clinics and initiated ART
in men at 1-year after the home-based HIV-positive test,
as well as prevalence of detectable viremia (detection limit
of > 1550 copies/ml) obtained from the DBS in men.
Changes in the number of HIV-related deaths and mortal-
ity rates in men and changes in the number of new HIV
infections and HIV incidence rates in young women 3
years after the home-based HIV test will be compared
across the arms. Secondary outcomes that will be mea-
sured in the study are shown in Table 1.
Data collection and measures
Participants are enrolled into the HITS trial during the on-
going annual individual HIV surveillance and routinely
followed up between 2018 and 2021 (BREC Ref: BE290/16).
Trained fieldworkers visit participants at home once a
year to conduct household and individual surveys using
tablet-based computers. Data on demographic information,
general health, and sexual behaviour (including contracep-
tive use, sexual activity and pregnancy history) are
collected via the REDCap database [27]. Participating indi-
viduals are offered rapid HIV testing. Consenting individ-
uals undergo confidential HIV pre- and post-test
counselling according to the Department of Health proce-
dures. A rapid HIV test is performed and test results are
provided approximately 20min after the testing. Partici-
pants who consent to the HIV surveillance have blood col-
lected on a filter paper as DBS, which are stored at the
AHRI Biorepository in Durban [28]. A 4th generation HIV
ELISA (Genscreen™ ULTRA HIV Ag-Ab (Biorad, Marnes-
la-Coquette, France) adopted and evaluated in-house by
the AHRI Diagnostic Research Laboratory (unpub-
lished data) is used for testing of all DBS samples. All
HIV ELISA positive DBS samples are subjected to
HIV viral load determination using the automated
Nuclisens EasyMag® (Biomerieux, Marcy-l’Etiole,
France). Viral load testing is performed on the same
day as the extraction.
Individuals who test positive for HIV are referred to the
nearby Department of Health clinics to receive HIV care
within 10 days of the HIV test date. Data on linkage to
care is collected from the Department of Health through
TIER.net (i.e. an electronic patient records management
system that contains information on all clinic visits for
people on ART, including data for all patients attending
the 17 clinics in the Hlabisa health sub-district and the
Hlabisa hospital) and clinic attendance data (where date
and reason for attendance are collected for all consenting
individuals in the programme area who attend one of the
11 clinics serving the programme area). All deaths are
ascertained by verbal autopsies with closest care givers
using a questionnaire based on the INDEPTH/World
Health Organization (WHO) standard questionnaire [29].
Data is collected and managed by AHRI Research
Data management within the routine AHRI HIV and
demographic surveillance study databases as per
AHRI comprehensive study procedures. The database
has strictly restricted access via a data enclave on a
secure server.
Randomisation and blinding
Randomisation was performed by the trial statistician
prior to intervention rollout to ensure that each arm has
similar baseline HIV incidence rates among women aged
15 and 30 years. First, all 45 clusters were stratified by
HIV incidence in young women using data from 7605
young women aged 15 and 30 years old, who were resi-
dents in the PIPSA between 2006 and 2015 at least for 1
year. A total of 34551 person years and 1636 seroconver-
sion events have been recorded, yielding overall 4.7 new
infections per 100 person years. Then the 45 clusters
were divided into four strata according to their HIV inci-
dence rate such that stratum 1 comprises clusters with
the lowest incidence rate, while stratum 4 comprises
clusters with the highest incidence rate. Each of Arm 1,
2, and 3 consists of two clusters from each of the four
incidence stratum (thus a total of eight clusters per
arm). Arm 4 (SoC) consists of five clusters from each of
the incidence stratum 1, 2, and 4, and six clusters from
incidence stratum 3 (thus a total of 25-clusters). The
study is an open label trial.
Statistical methods
Power calculation
The study was powered to achieve a 25% reduction in
HIV incidence among females aged 15–30 years old in
the intervention arms. Using the AHRI’s actual HIV inci-
dence data, we assumed HITS interventions were deliv-
ered in 2011 and simulated the effect of HITS
interventions in 24 intervention communities after 3-
years of follow up between 2012 and 2014. Using a
simulation approach we then explored a scenario where
the interventions lead to a 25% reduction in Arm 1 (mi-
cro-incentives), 25% reduction in Arm 3 (male-sensitive
HIV specific counselling) and a 37% reduction in the
combined arm (Arm 2) after 3-years of follow up.
The results (Fig. 5) show that we would have been
able to detect this reduction in incidence in > 80% of
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Table 1 Secondary outcomes of the study
No Secondary outcome Description Time frame
1 HIV testing uptake at point
of test offer in women
% received rapid HIV test at home among those offered the test in women Baseline
2 HIV treatment linkage at 1
year in women
% who visited the Department of Health clinics in the study area and initiated
ART in women
Year 1
3 Population-level HIV viral
suppression (both sexes)
Change in proportion with detectable viremia in both men and women; HIV
testing and viral load measurements are performed on the DBS samples
collected during the annual individual survey
Year 1
4 Population-level HIV viral
suppression (both sexes)
Change in proportion with detectable viremia in both men and women; HIV
testing and viral load measurements are performed on the DBS samples
collected during the annual individual survey
Year 3
5 Population-level HIV viral
suppression in women
Change in proportion with detectable viremia in women; HIV testing and viral
load measurements are performed on the DBS samples collected during the
annual individual survey
Year 1
6 Population-level HIV viral
suppression in women
Change in proportion with detectable viremia in women; HIV testing and viral
load measurements are performed on the DBS samples collected during the
annual individual survey
Year 3
7 Population-level HIV viral
suppression in men
Change in proportion with detectable viremia in men; HIV testing and viral load
measurements are performed on the DBS samples collected during the annual
individual survey
Year 3
8 Population level HIV incidence Change in HIV incidence rate (number of HIV sero-conversions per 100 person-years
of follow up) in both men and women; HIV testing and viral load measurements
are performed on the DBS samples collected during the annual individual survey
Year 3
9 Population-level HIV-related
mortality (both sexes)
Change in HIV-related mortality rate measured as the number of HIV-related deaths
per 1000 person-years of observation in both men and women
Year 3
10 Population-level all-cause
mortality (both sexes)
Change in all-cause mortality rate measured as the number of all-cause deaths per
1000 person-years of observation in both men and women
Year 3
11 Population-level HIV-related
mortality in women
Change in HIV-related mortality rate measured as the number of HIV-related deaths
per 1000 person-years of observation in women
Year 3
12 Population-level HIV incidence
in men
Change in HIV incidence rate (number of HIV sero-conversions per 100 person-years
of follow up) in men; HIV testing and viral load measurements are performed on the
DBS samples collected during the annual survey
Year 3
13 HIV status knowledge in men
and women
% ever received a test result for HIV in men and women Year 1
14 HIV prevention knowledge in
men and women
% reporting ever hearing about pre-exposure prophylaxis (PrEP) Year 1
15 HIV treatment utilization in
men and women
% reporting ever taking up ART for own health in men and women Year 1
16 Reported condom use in men
and women
% reporting condom use at last sex in men and women Year 1
17 Tuberculosis (TB) healthcare
utilization in men and women
% reported starting TB treatment in the past 12 months in men and women Year 1
18 Diabetes Healthcare utilization
in men and women
% reported starting diabetes treatment in the past 12 months Year 1
19 Hypertension healthcare utilization
in men and women
% reported starting blood pressure treatment in the past 12 months in men and
women
Year 1
20 Household wealth (household
assets)
Number of household assets (selected from a predefined list of 32 assets) Year 3
21 Household wealth (food security) % of adults in the household ever cutting the size of meals or missing meals due
to insufficient money for food in the past 12 months
Year 3
22 Partnership patterns in men
and women
% reporting having more than one sexual partner in the past 12 months in men and
women
Year 1
23 Retention in HIV care in men
and women
% who are retained in care (% patients having an ART clinic visit in previous 3 months)
at 1-year post-initiation in men and women
Year 1
24 Retention in HIV care in men
and women
% who are retained in care (% patients having an ART clinic visit in previous 3 months)
at 3 years post-initiation in men and women
Year 3
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simulation replicates (p < 0.05). Therefore, if we were
to introduce the HITS intervention in 2018 and fol-
low young females up for at least 3 years post-inter-
vention (i.e. utilize a total of 17 years of incidence
data – 2004 to 2021), we would be in excess of 90%
power to detect such a reduction in incidence in this
critical age-group.
In the total of 24 communities in the intervention
arms, an estimated total of 4,667 individuals will
receive a HITS intervention. In the 21 communities,
an estimated 4,900 individuals will receive the stand-
ard-of-care.
Statistical analysis
All primary analyses (both primary and secondary end-
points) will be intent-to-treat (ITT). For the binary primary
outcomes – HIV testing uptake and HIV treatment linkage
– we will use generalized linear models with Poisson distri-
bution, log link function, and robust error terms to deter-
mine effect sizes (risk ratios). We will fit beta regression
models for incidence and mortality rates [30, 31]. We will
also adjust for both baseline endpoints and clustering
through random effects. Under the difference-in-differ-
ences study design, the individuals are followed in two pe-
riods of time: the “before” and the “after” period, where the
interventions occur in the “after” period [32]. The goal of
the statistical analysis is to estimate the average treatment
effect for the treated clusters (week blocks). We will make
the usual assumption of parallel trend, that is, on average,
the outcomes for all the clusters in the four arms would
have followed a parallel path over time in the absence of
the intervention [33]. Our generalized linear models will in-
clude fixed effects for the “before” and the “after” time pe-
riods, the grouping of the clusters in four arms, and the
interaction between time periods and arms.
For the two survival-analytic primary endpoints – popu-
lation-level mortality among men and population-level HIV
incidence among women – we will use the Cox propor-
tional hazards model to determine effect sizes (hazard ra-
tios). If the proportional hazards assumption of the Cox
model is violated, we will use appropriate alternative sur-
vival analytic models. We will use data from the period
2004–2017 for baseline endpoint adjustment. In addition,
to the ITT analyses, we will measure intervention effects
adjusted for non-compliance using instrumental variable
(IV) approaches.
Process evaluation
In order to determine how the implementation of the HITS
intervention is achieved in our setting as well as the pro-
cesses through which the interventions affect outcomes, we
will gather stakeholder views in a purposive sample of up
to 150 stakeholders (HITS participants, fieldworkers and
health professionals) using mixed methods of quantitative
and qualitative techniques (e.g. surveys and in-depth inter-
views). The evaluation is shaped by the UK Medical
Table 1 Secondary outcomes of the study (Continued)
No Secondary outcome Description Time frame
25 Patient viral suppression
in men and women
% who are remain virally suppressed (% patients where virus
is undetectable) 1-year post-initiation in men and women
Year 1
26 Patient viral suppression
in men and women
% who are remain virally suppressed (% patients where virus
is undetectable) 3-years post-initiation in men and women
Year 3
Fig. 5 Power calculations. Example of data simulations to determine sample size required to detect a 25% decrease in HIV incidence in females
aged 15–30 years (in Arm 1 or 3 relative to the SoC arm) using the AHRI population-based HIV surveillance data (2004–2014)
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Research Council (MRC) guidance on the process evalu-
ation of complex interventions [34]. The guidelines identify
three important pathways of understanding the process of
achieving a particular outcome: a) Context – we will exam-
ine how the socio-cultural context of our setting influences
the development process, delivery and functioning of the
HITS interventions; b) Implementation of the HITS pro-
gram - we will describe the resources and processes
through which HITS implementation is achieved, and the
extent to which HITS intervention would be delivered as
intended or needed any program adaptations; c) Mecha-
nisms of impact - we will examine how study participants
respond to and interact with HITS interventions and
whether these interventions promote behavioural change
or not. In order to examine the ‘causal assumptions’ of the
intervention, the evaluation is informed by the Normalisa-
tion Process Theory (NPT) [35]. The theory will help us to
understand how the HITS intervention would be delivered,
as well as any changes that could affect its fidelity. All inter-
views will be recorded and transcribed and subject to the-
matic analysis following an interpretivist approach.
Cost-effectiveness analysis
We will conduct a cost-effectiveness analysis of the two in-
terventions, the micro-incentives and EPIC-HIV, from the
societal perspective. A time and motion study will be
conducted to determine how much time fieldworkers
spend on the HITS related activities including consenting
for study participation, HIV testing, counselling, and
provision of micro-incentives and/or EPIC-HIV. Detailed
information on direct and indirect costs will be docu-
mented during the study implementation to determine the
unit costs of providing the interventions. Effectiveness will
be measured as the number of uptake of HIV testing, new
HIV diagnosis, as well as linkage to care. We will also fit
mathematical modelling to simulate dynamic HIV trans-
mission calibrated to the data from the trial and the AHRI
surveillance and estimate disability-adjusted life years
(DALYs) over 10 years. We will calculate the incremental
cost-effectiveness ratio (ICER) for adding the interventions
to standard of care.
Discussion
The HITS trial will provide evidence for the impact and
feasibility of micro-incentives and a male-sensitive HIV
specific decision-support application to increase uptake of
home-based HIV testing and linkage to HIV care, so as to
reduce HIV-related mortality in men and population-level
HIV incidence in young women in the hyperendemic rural
South African setting. The study will also establish the
mechanisms and the determinants of successful imple-
mentation through comprehensive process evaluation.
Combination of quantitative and qualitative social science
research produced from this study will be essential to
understand the behavioural and social impact of offering
micro-incentives and male-sensitive HIV specific decision
support on the HIV care continuum and population-level
health outcomes in this rural hyperendemic South African
and other similar settings.
Trial status
The study is ongoing. Intervention delivery started in
February 2018 and ended in December 2018. Participant
follow-up will continue until the end of 2021. No articles
containing the results of this study have been published
or submitted for publication.
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